Stem cell–derived model offers insights on gene activity and addiction
Researchers at North Carolina State University have demonstrated that neuron-like cells derived from human stem cells can serve as a model for studying changes in the nervous system associated with addiction. The work sheds light on the effect of dopamine on gene activity in neurons, and offers a blueprint for related research moving forward.
“It is extremely difficult to study how addiction changes the brain at a cellular level in humans — nobody wants to experiment on somebody’s brain,” says , corresponding author of the study and an assistant professor of chemical and biomolecular engineering at NC State. “What we’ve done here demonstrates that we can gain a deep understanding of those cellular responses using neuronlike cells derived from human stem cells.”
At issue is how cells in our nervous system respond to drugs that are associated with substance abuse and addiction. Our bodies produce a neurotransmitter called dopamine. It’s associated with feelings, such as pleasure, that are related to motivation and reward. When neuronal cells in the brain’s “reward pathway” are exposed to dopamine, the cells activate a specific suite of genes, triggering the feelings of reward that can make people feel good. Many drugs — from alcohol and nicotine to opioids and cocaine — cause the body to produce higher levels of dopamine.
“In experiments using rodents, researchers have shown that when relevant neuronal cells are exposed to high levels of dopamine for an extended period of time, they become desensitized — meaning the cells’ gene activation is less pronounced in response to the dopamine,” Keung says. “This is called gene desensitization. However, until now, it hasn’t been possible to do an experimental study using human neuronal cells.”
“Our work here is the first experimental study to demonstrate gene desensitization in human neuronal cells, specifically in response to dopamine,” says , first author of the study and a Ph.D. student at NC State. “We don’t have to infer that it is happening in human cells; we can show that it is happening in human cells.”
In their , Tam and Keung exposed neuronlike cells derived from human stem cells to varying levels of dopamine for varying periods of time. The researchers found that when cells were exposed to high levels of dopamine for an extended period of time, the relevant “reward” genes became significantly less responsive. The work was published in the journal Cells.

“This is an interesting finding, but it’s also a proof of concept study,” Tam says. “We’ve demonstrated that gene desensitization to dopamine occurs in human cells, but there is still a lot we don’t know about the nature of the relationship between dopamine and gene desensitization.
“For example, could higher levels of dopamine cause desensitization at shorter time scales? Or could lower levels of dopamine cause desensitization at longer time scales? Are there threshold levels, or is there some sort of linear relationship? How might the presence of other neurotransmitters or bioactive chemicals affect these responses?”
“Those are good questions, which future research could address,” says Keung. “And we’ve demonstrated that these neuronlike cells derived from human stem cells are a good model for conducting that research.”
This article was republished with permission from North Carolina State University. Read the original.
Enjoy reading 91ӰToday?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91ӰToday
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17–21 in Cambridge, Massachusetts.